-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33

Benzinga·09/25/2026 12:48:23
Listen to the news
Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.